The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
In Chinese people with T2D suboptimally controlled with OADs, once-daily iGlarLixi provided better glycaemic control with BW benefit and lower hypoglycaemia event rates versus IDegAsp.
PDF的下载单位、IP信息已删除
(2025-6-4)
蓝天
潇洒的惋清
CFD
东方元语
无极微光
AllRightReserved
东大A111
Nexus
cdercder
尊嘟假嘟
张欢馨
科研狗
lizishu
归尘
敬老院N号
Avalonx
初景
GingerF
乐空思
贪玩的秋柔
皖公网安备34019202002308
